AlphaNet Coordinators

Zemaira CareZ provides support from fellow Alphas.

Meet your Alpha-1 AlphaNet Coordinators*

AlphaNet is a not-for-profit organization serving the specific needs of Alphas. Zemaira CareZ gives you the opportunity to connect to AlphaNet Coordinators who can provide long-term support and guidance on managing Alpha-1.

AlphaNet Coordinators are fellow Alpha-1 patients who can help support you through the challenges of your initial diagnosis. While they are not healthcare professionals or medical experts, they have been trained to provide education about Alpha-1 and therapy, answer nonmedical questions, and explain the services available to you through Zemaira CareZ and other Alpha-1 patient support. In short, they’ve been where you are and can offer a unique perspective.

Your AlphaNet Coordinator can help you:

  • Understand Alpha-1.
  • Understand what is involved in getting started with therapy.
  • Connect to the Alpha-1 community.
  • Connect with resources to help you afford therapy.
  • Get answers or resolve issues relating to your treatment.

*AlphaNet Coordinators are neither healthcare professionals nor medical experts. Their assistance does not constitute professional guidance, therapy, or psychological counseling. Always contact your physician with medical questions. For their time and expenses, AlphaNet Coordinators are compensated by AlphaNet Inc., an independent, not-for-profit, 501(c)(3) health management organization.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006d 12/2014